AU2013286729B2 - Inhibitors of hepatitis C virus - Google Patents

Inhibitors of hepatitis C virus Download PDF

Info

Publication number
AU2013286729B2
AU2013286729B2 AU2013286729A AU2013286729A AU2013286729B2 AU 2013286729 B2 AU2013286729 B2 AU 2013286729B2 AU 2013286729 A AU2013286729 A AU 2013286729A AU 2013286729 A AU2013286729 A AU 2013286729A AU 2013286729 B2 AU2013286729 B2 AU 2013286729B2
Authority
AU
Australia
Prior art keywords
alkyl
mmol
groups
optionally substituted
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013286729A
Other languages
English (en)
Other versions
AU2013286729A1 (en
Inventor
Kyla Bjornson
Eda Canales
Jeromy J. Cottell
Kapil Kumar KARKI
Ashley Anne Katana
Darryl Kato
Tetsuya Kobayashi
John O. Link
Ruben Martinez
Barton W. Phillips
Hyung-Jung Pyun
Michael Sangi
Adam James SCHRIER
Dustin Siegel
James G. Taylor
Chinh Viet Tran
Teresa Alejandra Trejo Martin
Randall W. Vivian
Zheng-Yu Yang
Jeff Zablocki
Sheila Zipfel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48803614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013286729(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU2013286729A1 publication Critical patent/AU2013286729A1/en
Application granted granted Critical
Publication of AU2013286729B2 publication Critical patent/AU2013286729B2/en
Priority to AU2016200201A priority Critical patent/AU2016200201A1/en
Priority to AU2016200670A priority patent/AU2016200670A1/en
Priority to AU2017203984A priority patent/AU2017203984B2/en
Assigned to GILEAD PHARMASSET LLC reassignment GILEAD PHARMASSET LLC Request for Assignment Assignors: GILEAD SCIENCES, INC.
Priority to AU2019222909A priority patent/AU2019222909B2/en
Priority to AU2021204238A priority patent/AU2021204238A1/en
Assigned to GILEAD SCIENCES, INC. reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: GILEAD PHARMASSET LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2013286729A 2012-07-03 2013-07-02 Inhibitors of hepatitis C virus Active AU2013286729B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2016200201A AU2016200201A1 (en) 2012-07-03 2016-01-13 Inhibitors of Hepatitis C virus
AU2016200670A AU2016200670A1 (en) 2012-07-03 2016-02-03 Inhibitors of Hepatitis C virus
AU2017203984A AU2017203984B2 (en) 2012-07-03 2017-06-13 Inhibitors of Hepatitis C virus
AU2019222909A AU2019222909B2 (en) 2012-07-03 2019-08-29 Inhibitors of Hepatitis C virus
AU2021204238A AU2021204238A1 (en) 2012-07-03 2021-06-23 Inhibitors of Hepatitis C virus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667806P 2012-07-03 2012-07-03
US61/667,806 2012-07-03
US201361798524P 2013-03-15 2013-03-15
US61/798,524 2013-03-15
PCT/US2013/049119 WO2014008285A1 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis c virus

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2016200201A Division AU2016200201A1 (en) 2012-07-03 2016-01-13 Inhibitors of Hepatitis C virus
AU2016200670A Division AU2016200670A1 (en) 2012-07-03 2016-02-03 Inhibitors of Hepatitis C virus

Publications (2)

Publication Number Publication Date
AU2013286729A1 AU2013286729A1 (en) 2015-01-22
AU2013286729B2 true AU2013286729B2 (en) 2015-11-12

Family

ID=48803614

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2013286729A Active AU2013286729B2 (en) 2012-07-03 2013-07-02 Inhibitors of hepatitis C virus
AU2016200201A Abandoned AU2016200201A1 (en) 2012-07-03 2016-01-13 Inhibitors of Hepatitis C virus
AU2016200670A Abandoned AU2016200670A1 (en) 2012-07-03 2016-02-03 Inhibitors of Hepatitis C virus
AU2017203984A Active AU2017203984B2 (en) 2012-07-03 2017-06-13 Inhibitors of Hepatitis C virus
AU2019222909A Active AU2019222909B2 (en) 2012-07-03 2019-08-29 Inhibitors of Hepatitis C virus
AU2021204238A Abandoned AU2021204238A1 (en) 2012-07-03 2021-06-23 Inhibitors of Hepatitis C virus

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2016200201A Abandoned AU2016200201A1 (en) 2012-07-03 2016-01-13 Inhibitors of Hepatitis C virus
AU2016200670A Abandoned AU2016200670A1 (en) 2012-07-03 2016-02-03 Inhibitors of Hepatitis C virus
AU2017203984A Active AU2017203984B2 (en) 2012-07-03 2017-06-13 Inhibitors of Hepatitis C virus
AU2019222909A Active AU2019222909B2 (en) 2012-07-03 2019-08-29 Inhibitors of Hepatitis C virus
AU2021204238A Abandoned AU2021204238A1 (en) 2012-07-03 2021-06-23 Inhibitors of Hepatitis C virus

Country Status (40)

Country Link
US (7) US20150175655A1 (https=)
EP (4) EP3825312A1 (https=)
JP (4) JP6025977B2 (https=)
KR (3) KR101610575B1 (https=)
CN (2) CN104540832B (https=)
AP (1) AP3903A (https=)
AR (1) AR091661A1 (https=)
AU (6) AU2013286729B2 (https=)
BR (2) BR122021012378B1 (https=)
CA (1) CA2877005C (https=)
CL (1) CL2014003634A1 (https=)
CO (1) CO7160104A2 (https=)
CR (1) CR20150045A (https=)
CY (2) CY1118379T1 (https=)
DK (2) DK3159345T3 (https=)
EA (2) EA033961B1 (https=)
EC (1) ECSP15002066A (https=)
ES (3) ES2605383T3 (https=)
HR (2) HRP20161379T1 (https=)
HU (2) HUE042345T2 (https=)
IL (4) IL236500B (https=)
IN (1) IN2014MN02598A (https=)
LT (2) LT2870160T (https=)
MD (2) MD20180040A2 (https=)
ME (2) ME02547B (https=)
MX (2) MX360597B (https=)
MY (1) MY173342A (https=)
NZ (2) NZ703064A (https=)
PE (1) PE20150204A1 (https=)
PH (3) PH12014502862B1 (https=)
PL (2) PL2870160T3 (https=)
PT (2) PT2870160T (https=)
RS (2) RS55494B1 (https=)
SG (3) SG10201702950TA (https=)
SI (2) SI2870160T1 (https=)
SM (3) SMT201900167T1 (https=)
TW (1) TWI602822B (https=)
UA (1) UA119315C2 (https=)
UY (1) UY34888A (https=)
WO (1) WO2014008285A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014145095A1 (en) * 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
JP6568541B2 (ja) 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
AU2014370125B2 (en) * 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CN107250097B (zh) * 2015-02-16 2020-08-07 中央硝子株式会社 含氟α-酮羧酸酯类的实用制造方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
JOP20170127A1 (ar) * 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
MA46268B1 (fr) 2016-09-22 2020-08-31 Astrazeneca Ab Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
EP3577100A4 (en) * 2017-02-01 2021-03-10 Abbvie Inc. ENZYMATIC PROCESS FOR THE PRODUCTION OF (±) -2- (DIFLUOROMETHYL) -1- (ALCOXYCARBONYL) -CYCLOPROPANECARBONIC ACID AND (±) -2- (VINYL) -1- (ALCOXYCARBONYLURE) -CYCLOPROPANEC
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
CN111018795B (zh) * 2019-12-25 2023-03-28 上海彩迩文生化科技有限公司 一种碱性条件下合成喹喔啉-3-酮的方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016441A1 (en) * 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP4312711B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
JP4271148B2 (ja) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
KR101031825B1 (ko) 2003-04-18 2011-04-29 이난타 파마슈티칼스, 인코포레이티드 거대고리형 퀴녹살리닐 ｃ형 간염 세린 단백질분해효소억제제
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RS51974B (sr) 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
MX2008001166A (es) 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
AU2006301966A1 (en) 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
KR20090024834A (ko) 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CN101583372A (zh) 2006-10-24 2009-11-18 默克公司 Hcv ns3蛋白酶抑制剂
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
AU2007318164B2 (en) 2006-10-27 2013-02-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057209A1 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
EP2160392A2 (en) 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
US20090005387A1 (en) 2007-06-26 2009-01-01 Deqiang Niu Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
WO2009014730A1 (en) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
WO2009042668A2 (en) 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8106059B2 (en) 2007-10-24 2012-01-31 Virobay, Inc. Substituted pyrazines that inhibit protease cathepsin S and HCV replication
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
WO2009070689A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
CN101932242A (zh) 2007-12-05 2010-12-29 益安药业 喹喔啉基衍生物
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
MX2010006736A (es) 2007-12-21 2010-10-15 Avila Therapeutics Inc Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2713005A1 (en) 2008-01-24 2009-07-30 Enanta Pharmaceuticals, Inc. Difluorinated tripeptides as hcv serine protease inhibitors
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
AU2009217551B2 (en) 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
WO2009114633A1 (en) 2008-03-12 2009-09-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
EA201071034A1 (ru) 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
PT2540350E (pt) 2008-07-22 2014-08-27 Merck Sharp & Dohme Combinações de um composto de quinoxalina macrocílico o qual é um inibidor da protease ns3 do hcv com outros agentes do hcv
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
EP2334680A2 (en) 2008-08-20 2011-06-22 Sequoia Pharmaceuticals, Inc. Hcv protease inhibitors
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
PE20130307A1 (es) 2008-09-16 2013-03-22 Boehringer Ingelheim Int Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100080770A1 (en) 2008-09-29 2010-04-01 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2358736A1 (en) 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides
WO2010048468A1 (en) 2008-10-23 2010-04-29 Concert Pharmaceuticals, Inc. Deuterated macrocyclic inhibitors of viral ns3 protease
CA2743912A1 (en) 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
KR20110087297A (ko) 2008-11-21 2011-08-02 베링거 인겔하임 인터내셔날 게엠베하 경구 투여용의 강력한 ｈｃｖ 억제제의 약제학적 조성물
US20100272674A1 (en) 2008-12-04 2010-10-28 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
KR20110096557A (ko) 2008-12-10 2011-08-30 아칠리온 파르마세우티칼스 인코포레이티드 바이러스 복제의 억제제로서 4-아미노-4-옥소부타노일 펩티드 사이클릭 유사체
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102300871A (zh) 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
SI2382198T1 (sl) 2008-12-23 2013-11-29 Janssen Pharmaceuticals, Inc. Postopek in vmesne spojine za pripravo makrocikličnega inhibitorja HCV proteaze
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
CA2763122A1 (en) 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
UA103807C2 (ru) 2009-07-31 2013-11-25 Кадила Хелткере Лимитед Замещенные бензамидные производные как активаторы глюкокиназы (gk)
EP2470189A4 (en) 2009-08-27 2013-01-23 Merck Sharp & Dohme METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
IN2012DN02693A (https=) 2009-09-28 2015-09-04 Intermune Inc
TW201116540A (en) 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
US9193740B2 (en) 2009-10-19 2015-11-24 Enanta Pharmaceuticals, Inc. Bismacrocyclic compounds as hepatitis C virus inhibitors
NZ602288A (en) 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
WO2011156337A2 (en) 2010-06-07 2011-12-15 Abbott Laboratories Macrocyclic hepatitis c serine protease inhibitors
WO2012019299A1 (en) 2010-08-11 2012-02-16 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2012037259A1 (en) 2010-09-15 2012-03-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
JP5857053B2 (ja) * 2010-09-21 2016-02-10 エナンタ ファーマシューティカルズ インコーポレイテッド 大環式プロリン由来ｈｃｖセリンプロテアーゼ阻害剤
EP2618665A4 (en) 2010-09-21 2014-08-20 Merck Sharp & Dohme HCV NS3 proteinase inhibitor
US20120095211A1 (en) 2010-09-22 2012-04-19 Intermune, Inc. Substituted proline inhibitors of hepatitis c virus replication
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
EP2651884A2 (en) 2010-12-14 2013-10-23 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012166459A1 (en) 2011-05-27 2012-12-06 Bristol-Myers Squibb Company Tripeptides incorporating deuterium as inhibitors of hepatitis c virus
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
US20140328799A1 (en) 2011-10-31 2014-11-06 Steven S. Carroll Compositions useful for the treatment of viral diseases
US9328138B2 (en) 2011-11-15 2016-05-03 Msd Italia S.R.L. HCV NS3 protease inhibitors
HK1204982A1 (en) 2012-01-12 2015-12-11 勃林格殷格翰国际有限公司 Stabilized pharmaceutical formulations of a potent hcv inhibitor
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016441A1 (en) * 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
JP2015523365A (ja) 2015-08-13
SG11201408739VA (en) 2015-01-29
CO7160104A2 (es) 2015-01-15
US20160361375A1 (en) 2016-12-15
HRP20190578T1 (hr) 2019-05-17
MX2018013668A (es) 2019-01-28
JP6025977B2 (ja) 2016-11-16
EP3492464A1 (en) 2019-06-05
DK3159345T3 (en) 2019-03-25
IL236500A0 (en) 2015-02-26
SMT201900167T1 (it) 2019-05-10
TW201414740A (zh) 2014-04-16
BR112014033080B1 (pt) 2022-03-29
AU2013286729A1 (en) 2015-01-22
AR091661A1 (es) 2015-02-18
JP2016041743A (ja) 2016-03-31
HK1210151A1 (en) 2016-04-15
US20190008858A1 (en) 2019-01-10
SMT201600470T1 (it) 2017-03-08
AU2019222909A1 (en) 2019-09-19
PT3159345T (pt) 2019-04-15
LT2870160T (lt) 2016-12-12
PH12020550552A1 (en) 2021-07-26
CA2877005C (en) 2016-12-13
CR20150045A (es) 2015-05-13
CL2014003634A1 (es) 2015-11-06
CY1118379T1 (el) 2017-06-28
US9655944B2 (en) 2017-05-23
IL261581B (en) 2019-10-31
ME02547B (me) 2017-02-20
DK2870160T3 (en) 2017-01-23
RS55494B1 (sr) 2017-04-28
KR102040023B1 (ko) 2019-11-05
EP2870160A1 (en) 2015-05-13
US20160130300A1 (en) 2016-05-12
SI3159345T1 (sl) 2019-03-29
EP3159345B1 (en) 2019-01-09
ME03362B (me) 2019-10-20
US20170290827A1 (en) 2017-10-12
US9296782B2 (en) 2016-03-29
EA201492214A1 (ru) 2015-10-30
EA033961B1 (ru) 2019-12-13
CN104540832B (zh) 2016-08-24
UY34888A (es) 2014-01-31
EA201790661A3 (ru) 2017-10-31
IN2014MN02598A (https=) 2015-07-24
IL252446A0 (en) 2017-07-31
EP3825312A1 (en) 2021-05-26
PH12016502040A1 (en) 2019-02-27
SG10201702950TA (en) 2017-06-29
AU2016200670A1 (en) 2016-02-25
IL261581A (en) 2018-10-31
IL269662A (en) 2019-11-28
NZ703064A (en) 2016-12-23
PE20150204A1 (es) 2015-02-12
MD4602B1 (ro) 2018-11-30
EP3492464B1 (en) 2020-08-19
AU2017203984B2 (en) 2019-06-06
MD20140136A2 (ro) 2015-05-31
SMT201600470B (it) 2017-03-08
HUE042345T2 (hu) 2019-06-28
RS58409B1 (sr) 2019-04-30
CY1121418T1 (el) 2020-05-29
EA201790661A2 (ru) 2017-08-31
AU2016200201A1 (en) 2016-02-04
AP2014008166A0 (en) 2014-12-31
EA027390B1 (ru) 2017-07-31
LT3159345T (lt) 2019-03-12
KR20160040743A (ko) 2016-04-14
ECSP15002066A (es) 2015-11-30
US20190365748A1 (en) 2019-12-05
AP3903A (en) 2016-11-17
US20150175655A1 (en) 2015-06-25
UA119315C2 (uk) 2019-06-10
MD20180040A2 (ro) 2018-11-30
JP2018154651A (ja) 2018-10-04
ES2716138T3 (es) 2019-06-10
IL236500B (en) 2018-02-28
SG10201912269YA (en) 2020-02-27
HUE032404T2 (en) 2017-09-28
WO2014008285A1 (en) 2014-01-09
CN104540832A (zh) 2015-04-22
EP3159345A1 (en) 2017-04-26
PH12014502862A1 (en) 2015-02-23
MX360597B (es) 2018-11-09
US10603318B2 (en) 2020-03-31
AU2019222909B2 (en) 2021-03-25
PL3159345T3 (pl) 2019-09-30
US20140017198A1 (en) 2014-01-16
TWI602822B (zh) 2017-10-21
MY173342A (en) 2020-01-17
ES2827300T3 (es) 2021-05-20
ES2605383T3 (es) 2017-03-14
JP2020143107A (ja) 2020-09-10
EP2870160B1 (en) 2016-09-28
HK1209416A1 (en) 2016-04-01
SI2870160T1 (sl) 2016-11-30
KR20190124346A (ko) 2019-11-04
BR122021012378B1 (pt) 2022-05-10
MX2014015846A (es) 2015-08-14
CA2877005A1 (en) 2014-01-09
PL2870160T3 (pl) 2017-05-31
HRP20161379T1 (hr) 2016-12-02
PH12014502862B1 (en) 2015-02-23
US10335409B2 (en) 2019-07-02
KR20150034698A (ko) 2015-04-03
AU2017203984A1 (en) 2017-07-06
AU2021204238A1 (en) 2021-07-22
CN106117309B (zh) 2019-08-30
BR112014033080A2 (pt) 2017-06-27
CN106117309A (zh) 2016-11-16
KR101610575B1 (ko) 2016-04-07
PT2870160T (pt) 2016-12-12
NZ739248A (en) 2019-05-31

Similar Documents

Publication Publication Date Title
AU2013286729B2 (en) Inhibitors of hepatitis C virus
HK1236517A1 (en) Inhibitors of hepatitis c virus
HK1236517A (en) Inhibitors of hepatitis c virus
HK1236517B (en) Inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GILEAD PHARMASSET LLC

Free format text: FORMER OWNER(S): GILEAD SCIENCES, INC.

PC Assignment registered

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER(S): GILEAD PHARMASSET LLC